Identification of TMEM217 as a novel prognostic biomarker and potential therapeutic target in acute myeloid leukemia  

作　　者：Yunying Yao Zhizhou Xi Min Wu Bo Jiao Jiaming Gao Donghe Li Xi Xie Pengfei Xu Jiaoyang Li Lei Yan Ruibao Ren Ping Liu 

机构地区：[1]Shanghai Institute of Hematology,State Key Laboratory for Medical Genomics,National Research Center for Translational Medicine,Collaborative Innovation Center of Hematology,Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China [2]International Center for Aging and Cancer,Hainan Medical University,Haikou,Hainan 570102,China

出　　处：《Genes & Diseases》2024年第4期90-93,共4页基因与疾病（英文）

基　　金：supported by the Key Project of the National Natural Science Foundation of China(No.82230088 to R.R.);National Natural Science Foundation of China(No.81870112,82170147 to R.R.,No.81970134,82170111 to P.L.,No.82200200 to Z.X.);Shanghai Science and Technology Development Funds(China)(No.20Z11900200 to R.R.,No.18ZR1423600 to P.L);Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research(China)(No.2019CXJQ01 to R.R.);the Samuel Waxman Cancer Research Foundation(to R.R.);the Innovative Research Team of High-level Local Universities in Shanghai,China(to R.R.);the National Key Research and Development Program of China(No.2022YFC2705004 to P.L.).

摘　　要：Despite remarkable advances in molecular and cell biology of acute myeloid leukemia(AML),AML patients still frequently relapse and have low 5-year overall survival(OS)rates.1 It is worth noting that a recent study from the registry or clinical trial compilation has reported an improvement in the OS of adult AML patients,especially those under 60 years of age.

关 键 词：ACUTE MYELOID LEUKEMIA 

分 类 号：R733.71[医药卫生—肿瘤]